Trends in Use of GLP-1 Medications
Irrespective of whether a patent in a patent family was a continuation, continuation-in-part, divisional application, or linked by a terminal disclaimer in terms of its expiry date, it was counted as a distinct patent
It immediately notes that individual variation is substantial and that metabolic, behavioral and medication-interaction factors all shift the timeline
For example, semaglutide 2.4 mg (Wegovy) yields approximately 15% body weight reduction in clinical trials, while lower doses used for diabetes (Ozempic) produce more modest weight loss
The weight of any such item can be found on its detail page
Diabetes Ther 15 , 547563 (2024)